← All trials
NCT06995144
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2025
- Primary completion
- Dec 15, 2025
- Completion date
- Mar 15, 2026
- First posted
- May 29, 2025
- Last posted
- Jul 4, 2025
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sarfez Pharmaceuticals, Inc.Lead sponsor
- Sarfez Pharmaceuticals, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.